Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer

Maternally expressed gene 3 (MEG3), a long non-coding RNA (lncRNA), has tumor-suppressor properties and its expression is lost in several human tumors. However, its biological role in esophageal squamous cell carcinoma (ESCC) tumorigenesis is poorly defined. The present study determined the role and methylation status of MEG3 in esophageal cancer cells and ESCC clinical specimens, and further observed the competing endogenous RNA (ceRNA) activity of MEG3 in the pathogenesis and development of ESCC. Significant downregulation of MEG3 was detected in esophageal cancer cells and ESCC tissues and the expression level of MEG3 was significantly increased in cancer cells after treated with the DNA methyltransferase inhibitor 5-Aza-dC. Upregulation of MEG3 led to the inhibition of proliferation and invasiveness of the cancer cells. The aberrant promoter hypermethylation of MEG3 indicates silencing of its expression. Furthermore, MEG3 acts as a ceRNA to regulate the expression of E-cadherin and FOXO1 by binding hsa-miR-9. Upregulation of miR-9 was detected in esophageal cancer cell lines and ESCC tissues, and miR-9 promoted esophageal cancer cell proliferation and invasion. Finally, downregulation and hypermethylation of MEG3 was associated with ESCC patients' survival. Implications: MEG3 functions as a tumor-suppressive lncRNA and aberrant promoter hypermethylation is critical for MEG3 gene silencing in ESCC. In addition, MEG3 acts as a ceRNA to regulate expression of E-cadherin and FOXO1 by competitively binding miR-9 and may be used as a potential biomarker in predicting ESCC patients' progression and prognosis. Mol Cancer Res; 15(7); 800–10. ©2017 AACR.

[1]  Jia Yu,et al.  Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate gastric cancer progression , 2015, Journal of experimental & clinical cancer research : CR.

[2]  Guang-Yan Yu,et al.  Expression, regulation and roles of miR‐26a and MEG3 in tongue squamous cell carcinoma , 2014, International journal of cancer.

[3]  T. Zeng,et al.  MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma , 2014, Oncotarget.

[4]  Tao Xi,et al.  FOXO1 3′UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity , 2014, FEBS letters.

[5]  Lei Yang,et al.  Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer. , 2014, Oncology reports.

[6]  G. Eslick,et al.  Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. , 2014, Journal of gastrointestinal oncology.

[7]  Wei Li,et al.  Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression , 2013, BMC Cancer.

[8]  Zunnan Huang,et al.  Long non-coding RNA: a new player in cancer , 2013, Journal of Hematology & Oncology.

[9]  Rong Yin,et al.  Long noncoding RNA: an emerging paradigm of cancer research , 2013, Tumor Biology.

[10]  Pengjun Wang,et al.  Overexpression of the long non‐coding RNA MEG3 impairs in vitro glioma cell proliferation , 2012, Journal of cellular biochemistry.

[11]  Yunli Zhou,et al.  MEG3 noncoding RNA: a tumor suppressor. , 2012, Journal of molecular endocrinology.

[12]  C. Croce,et al.  microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer , 2011, Oncogene.

[13]  D. Cacchiarelli,et al.  A Long Noncoding RNA Controls Muscle Differentiation by Functioning as a Competing Endogenous RNA , 2011, Cell.

[14]  E. Hatzimichael,et al.  MEG3 imprinted gene contribution in tumorigenesis , 2011, International journal of cancer.

[15]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[16]  R. Shiekhattar,et al.  Long non-coding RNAs and enhancers. , 2011, Current opinion in genetics & development.

[17]  Jiayi Wang,et al.  CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer , 2010, Nucleic acids research.

[18]  D. Louis,et al.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. , 2010, Cancer research.

[19]  Hongbin Lin,et al.  Genetic Heterogeneity of Oesophageal Cancer in High-Incidence Areas of Southern and Northern China , 2010, PloS one.

[20]  G. Dranitsaris,et al.  CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. , 2010, Leukemia research.

[21]  C. Stratakis,et al.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. , 2008, The Journal of clinical endocrinology and metabolism.

[22]  E. Hatzimichael,et al.  Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. , 2008, Clinical lymphoma & myeloma.

[23]  Jing Zhao,et al.  Activation of p53 by MEG3 Non-coding RNA* , 2007, Journal of Biological Chemistry.

[24]  Jing Zhao,et al.  Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. , 2005, The Journal of clinical endocrinology and metabolism.

[25]  A. Ferguson-Smith,et al.  Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour , 2005, British Journal of Cancer.

[26]  D. Danila,et al.  A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. , 2003, The Journal of clinical endocrinology and metabolism.

[27]  M. Isobe,et al.  Allelic imbalance of 14q32 in esophageal carcinoma. , 2002, Cancer genetics and cytogenetics.

[28]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[29]  K. Ohshima,et al.  Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki. , 2001, Blood.

[30]  M. Isobe,et al.  Loss of heterozygosity of 14q32 in colorectal carcinoma. , 1999, Cancer genetics and cytogenetics.

[31]  A. Mutirangura,et al.  Loss of heterozygosity on chromosome 14 in nasopharyngeal carcinoma , 1998, International journal of cancer.

[32]  T. Houseal,et al.  Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative `tumor progression' locus , 1997, Oncogene.

[33]  J. Luketich,et al.  Esophageal cancer: an update. , 2010, International journal of surgery.

[34]  Yunli Zhou,et al.  Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region. , 2006, The international journal of biochemistry & cell biology.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.